Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. Recent Forms 8‑K referenced in the input include announcements of quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in‑licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
BeOne Medicines insider sale and holdings summary. The reporting person, Global Head of R&D, disclosed a sale of 5,000 American Depositary Shares (ADS) executed under a Rule 10b5-1 trading plan at a weighted average price of $350.0623 per ADS. The report shows 1,023,529 ordinary shares previously reported as disposed and an indirect beneficial ownership position of 601,965 ordinary shares held through Wang Holdings LLC. The filer also disclosed a contribution of RMB10 million to an employee participation plan that purchased RMB-denominated shares in the issuer's STAR Market offering; the filer disclaims voting and dispositive power over those RMB Shares.
BeOne Medicines Ltd. (ONC) Form 144 notice reports a proposed sale of 9,010 ADS (American Depositary Shares) through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $3,163,681.30 and approximately 54,564,278 ADS outstanding. The filing shows the securities were mainly acquired via an exercise of stock options on 09/10/2025 (8,894 ADS, paid in cash) and restricted stock units on 06/15/2025 (116 ADS). The filer disclosed prior sales in the past three months: 9,342 ADS (10b5-1 sale) on 08/13/2025 for $2,805,905.17, 920 ADS on 07/30/2025 for $280,232.74, and 422 ADS on 06/16/2025 for $112,463.00. The notice includes the usual representation about absence of undisclosed material adverse information and reference to Rule 10b5-1 trading plans where applicable.
BeOne Medicines director Corazon D. Sanders reported multiple transactions on 09/05/2025. The filing shows a disposal of 57,226 Ordinary Shares, an acquisition and a subsequent disposition of 2,665 American Depositary Shares (ADS) on the same date with reported prices of $155.68 (acquisition) and $337 (disposition). The report also discloses a grant of a share option covering 34,645 ordinary shares with an exercise price of $11.98, exercisable under specified vesting conditions and expiring on 06/21/2032. Each ADS represents 13 ordinary shares. The form is signed by an attorney-in-fact on behalf of the reporting person on 09/09/2025.
BeOne Medicines Ltd. (ONC) Form 144 notice: The filer notified a proposed sale of 5,000 ADS through Morgan Stanley Smith Barney at an aggregate market value of $1,732,250.00, with an approximate sale date of 09/09/2025 on NASDAQ. The securities were acquired on 05/17/2022 by previously exercised stock options and paid in cash. The filing also discloses recent sales by the related parties: 7,675 ADS were sold during the past three months in multiple transactions generating gross proceeds of $2,210,354.28. The filer affirms no undisclosed material adverse information and, where applicable, reliance on a trading plan or instructions is noted in the form.
BeOne Medicines Ltd. (ONC) filing a Form 144 reports a proposed sale of 2,665 common shares with an aggregate market value of $898,105.00. The securities were acquired and are planned to be sold on 09/05/2025 following an exercise of options under a registered plan, with cash payment recorded on that date. The broker listed for the proposed sale is Morgan Stanley Smith Barney LLC, Executive Financial Services, New York and the sale is expected to occur on NASDAQ. The filer states there were no securities sold in the past three months by the selling person and includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
BeOne Medicines Ltd. insider transaction summary: Principal Accounting Officer Titus B. Ball reported sales on 09/02/2025. The filing shows a disposition of 72,397 Ordinary Shares and a sale of 122 American Depositary Shares at $326.76 per ADS. The filing explains each ADS represents 13 Ordinary Shares and that the ADS sale was executed to satisfy a mandatory tax withholding on vesting restricted share units; those units vest 1/4 on each anniversary of August 31, 2023, subject to continued service. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
BeOne Medicines Ltd. (ONC) Form 144 notifies a proposed sale of 122 American Depositary Shares (ADS) to be executed through Morgan Stanley Smith Barney LLC on 09/02/2025 on NASDAQ with an aggregate market value of $39,864.72. The filing reports the ADS were acquired on 08/31/2025 by restricted stock vesting under a registered plan and that payment/consideration is noted as Not Applicable.
The filing lists prior sales by the same person, Titus Benjamin Ball, of 134 ADS and 137 ADS on 06/11/2025 with gross proceeds of $34,620.05 and $26,021.78, respectively. Certain filer/contact fields and the notice date/signature are not populated in the provided content.
BeOne Medicines Ltd. furnished an 8-K to note that its STAR Interim Report for the six months ended June 30, 2025 was prepared under PRC GAAP (China Accounting Standards) as required by PRC Securities Laws. The filing states a supplemental exhibit (Exhibit 99.1) provides the company’s research and development expenses allocated by key products and other R&D projects prepared in accordance with U.S. GAAP, plus a summary of material differences between PRC GAAP and U.S. GAAP. The STAR Interim Report is available publicly in Chinese on the Shanghai Stock Exchange website, but that report and the SSE website content are explicitly not being filed with or incorporated into the company’s U.S. SEC filings. Information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and therefore is not subject to Section 18 liabilities.
BeOne Medicines entered a royalty sale with Royalty Pharma providing an upfront payment of $885 million at closing in exchange for a significant portion of tiered mid-single-digit royalties on Imdelltra (tarlatamab) sales outside China. The Seller retains other economic rights under the Amgen Collaboration Agreement and may, through August 25, 2026, exercise a put option to sell an additional portion of royalties for up to $65 million. The Seller will share in royalties on annual Imdelltra ex-China net revenue above $1.5 billion. All Amgen royalty payments to the Seller are to be deposited into an escrow account, and the agreement includes customary representations, warranties, covenants and indemnities. BeOne expects the upfront payment to become a material direct financial obligation at closing. The filing also discloses forward-looking statements and enumerates clinical, regulatory, intellectual property, funding and third-party risks.
Wu Xiaobin, President and COO of BeOne Medicines Ltd. (ONC), reported multiple transactions on 08/13/2025 and 08/14/2025 involving the company’s American Depositary Shares (ADS) and stock options. The filing states each ADS represents 13 ordinary shares. The reporting person sold multiple blocks of ADS under a Rule 10b5-1 trading plan adopted May 13, 2024 (amended May 14, 2025), with reported weighted-average sale prices ranging roughly from $300.00 to $308.12 across the transactions. The filing also shows a series of option grants/rights: 296,049, 352,105, 399,828, and 119,340 ordinary-share equivalents (various exercise prices and vesting schedules), and indicates direct and indirect ownership entries including shares held by the reporting person’s wife.